HUMABFC

Welcome to the Brand page for “HUMABFC”, which is offered here for Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing;scientific and technological services, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies;.

Its status is currently believed to be active. Its class is unavailable. “HUMABFC” is believed to be currently owned by “LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES”.